Johnson & Johnson reports its ceftobiprole is effective in treating diabetic foot infection in 86% of patients, based on data from Phase III clinical trials. The drug, which is being co-developed by J&J with Basilea Pharmaceutica Ltd., also appeared to work against infections caused by Staphylococcus aureus in some cases, the company reports.

Related Summaries